Evidence map›Paper›PMID 37223678›Full record

ArticleFrontiers in oncology2023

The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease.

Marianna V Papageorge, Renee M Maina, Amber Loren O King, Victor Lee, Raymond Baumann, Darko Pucar, Stephan Ariyan, Sajid A Khan, Sarah A Weiss, James Clune and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Marianna V PapageorgeDepartment of Surgery, Yale University School of Medicine, New Haven, CT, United States.
Renee M MainaDepartment of Surgery, The University of Tennessee Health Science Center, Memphis, TN, United States.
Amber Loren O KingYale University School of Medicine, New Haven, CT, United States.
Victor LeeYale University School of Medicine, New Haven, CT, United States.
Raymond BaumannDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, United States.
Darko PucarDepartment of Radiology, Yale University School of Medicine, New Haven, CT, United States.
Stephan AriyanDepartment of Surgery, Yale University School of Medicine, New Haven, CT, United States.
Sajid A KhanDepartment of Surgery, Yale University School of Medicine, New Haven, CT, United States.
Sarah A WeissRutgers Cancer Institute of New Jersey, Medical Oncology, New Brunswick, NJ, United States.
James CluneDepartment of Surgery, Yale University School of Medicine, New Haven, CT, United States.
Kelly OlinoDepartment of Surgery, Yale University School of Medicine, New Haven, CT, United States.
Yale University · USRutgers Cancer Institute of New JerseyUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Previous studies demonstrate minimal utility of pre-operative imaging for low-risk melanoma; however, imaging may be more critical for patients with high-risk disease. Our study evaluates the impact of peri-operative cross-sectional imaging in patients with T3b-T4b melanoma. Methods: Patients with T3b-T4b melanoma who underwent wide local excision were identified from a single institution (1/1/2005 - 12/31/2020). Cross-sectional imaging was defined as body CT, PET and/or MRI in the perioperative period, with the following findings: in-transit or nodal disease, metastatic disease, incidental cancer, or other. Propensity scores were created for the odds of undergoing pre-operative imaging. Recurrence free survival was analyzed using the Kaplan-Meier method and log-rank test. Results: A total of 209 patients were identified with a median age of 65 (IQR 54-76), of which the majority were male (65.1%), with nodular melanoma (39.7%) and T4b disease (47.9%). Overall, 55.0% underwent pre-operative imaging. There were no differences in imaging findings between the pre- and post-operative cohorts. After propensity-score matching, there was no difference in recurrence free survival. Sentinel node biopsy was performed in 77.5% patients, with 47.5% resulting in a positive result. Conclusion: Pre-operative cross-sectional imaging does not impact the management of patients with high-risk melanoma. Careful consideration of imaging use is critical in the management of these patients and highlights the importance of sentinel node biopsy for stratification and decision making.

Indexed as

cross-sectional imaginghigh-risk melanomarecurrence free survivalsentinel lymph node (SLN) biopsysurgical management

Identifiers

PMID37223678
PMCPMC10200883
OpenAlexW4375864372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.